. A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia. Am J Physiol Heart Circ Physiol 290: H1484 -H1492, 2006. First published November 23, 2005 doi:10.1152/ajpheart.01006.2005The therapeutic use of angiogenic factors shows promise in the treatment of critical limb ischemia; however, its potential for myonephropathic metabolic syndrome (MNMS), a fatal complication caused by arterial reconstruction, has not been elucidated. The objective of this study was to evaluate the effectiveness of recombinant Sendai virus-mediated gene transfer of fibroblast growth factor-2 (FGF-2) directly compared with that of a radical scavenger, MCI-186, in a rat model of MNMS. MNMS was surgically induced by aortic occlusion below renal arteries for 4 h, followed by 6 h of reperfusion. Administration of MCI-186 (twice; iv 5 min before induced ischemia and ip 5 min before reperfusion; 10 mg/kg, respectively), but not FGF-2 gene transfer (once, 48 h before induced ischemia), dramatically prevented the increase of serum biochemical markers as well as the edema of the gastrocnemius muscle. The effect of MCI-186 was accompanied by the marked suppression of the neutrophilic infiltration into the local (muscle) and remote (lung) organs. Although serum and muscular levels of a neutrophil-chemoattractant (growth-related oncogene/cytokine-induced neutrophil chemoattractant-1) were not affected by any treatment, the serum level of soluble intercellular adhesion molecule-1 was decreased by treatment with MCI-186 but not by treatment with FGF-2. These results suggest the distinct mechanism of MNMS from critical limb ischemia without reperfusion. Therefore, radical scavenging should be paid more attention than therapeutic angiogenesis when arterial circulation is reconstructed. fibroblast growth factor-2; free radicals; critical limb ischemia; neutrophils IN THE LAST DECADE, a number of experimental studies have suggested the possible utility of angiogenic growth factors ("therapeutic angiogenesis") to treat limb ischemia, as well as ischemic heart diseases (30,31,36). Emerging evidence in clinical trials for limb ischemia, however, has shown a relatively limited outcome of therapeutic angiogenesis, in both protein and gene therapies, in double-blinded placebo-controlled studies (17,23,26). Therefore, further effort should be put into the clinical evaluation of the potentials of therapeutic angiogenesis, including the choice of the angiogenic factors, optimized dose and local level of the dose, and indications for clinical stages (4, 5).In a recent series of experimental studies, we demonstrated that intramuscularly boosted expression of basic fibroblast growth factor (bFGF or FGF-2), which is a prototype polypeptide for angiogenesis, by a highly efficient gene transfer vector, recombinant Sendai virus (SeV) (37), constantly showed efficient therapeutic effects in acute severe hindlimb ischemia of mice (19,21,25,32), as well as chronic limb ischemia of rabbits (2...